Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michelle Pham

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
International Journal of Medical Informatics|July 4, 2026
Medical students' use of large language models: a national surveyAustin A Barr, Robert C Rozman, Kevin Liu, et al.
The Journal of Antimicrobial Chemotherapy|September 5, 2022
Pharmacokinetics of levonorgestrel and etonogestrel contraceptive implants over 48 weeks with rilpivirine- or darunavir-based antiretroviral therapyShadia Nakalema, Catherine A Chappell, Michelle Pham, et al.
Contraception|January 14, 2023
Pharmacokinetics of dose-adjusted levonorgestrel emergency contraception combined with efavirenz-based antiretroviral therapy or rifampicin-containing tuberculosis regimensKimberly K Scarsi, Laura M Smeaton, Anthony T Podany, et al.
Neuroethics|May 4, 2021
Recommendations for Responsible Development and Application of NeurotechnologiesSara Goering, Eran Klein, Laura Specker Sullivan, et al.
Pharmacogenetics and Genomics|June 12, 2023
Pharmacogenetic interactions of efavirenz or rifampin and isoniazid with levonorgestrel emergency contraception during treatment of HIV or tuberculosisNana Agyemang, Kimberly K Scarsi, Paxton Baker, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 17, 2021
Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose RifapentineAnthony T Podany, Michelle Pham, Erin Sizemore, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
International Journal of Medical Informatics|July 4, 2026
Medical students' use of large language models: a national surveyAustin A Barr, Robert C Rozman, Kevin Liu, et al.
The Journal of Antimicrobial Chemotherapy|September 5, 2022
Pharmacokinetics of levonorgestrel and etonogestrel contraceptive implants over 48 weeks with rilpivirine- or darunavir-based antiretroviral therapyShadia Nakalema, Catherine A Chappell, Michelle Pham, et al.
Contraception|January 14, 2023
Pharmacokinetics of dose-adjusted levonorgestrel emergency contraception combined with efavirenz-based antiretroviral therapy or rifampicin-containing tuberculosis regimensKimberly K Scarsi, Laura M Smeaton, Anthony T Podany, et al.
Neuroethics|May 4, 2021
Recommendations for Responsible Development and Application of NeurotechnologiesSara Goering, Eran Klein, Laura Specker Sullivan, et al.
Pharmacogenetics and Genomics|June 12, 2023
Pharmacogenetic interactions of efavirenz or rifampin and isoniazid with levonorgestrel emergency contraception during treatment of HIV or tuberculosisNana Agyemang, Kimberly K Scarsi, Paxton Baker, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 17, 2021
Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose RifapentineAnthony T Podany, Michelle Pham, Erin Sizemore, et al.
Pageof 3